Picture used for illustrative purpose. File
AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday.
The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout.
"On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," AstraZeneca said.
It added that safety reviewers had recommended to Britain's Medicines Health Regulatory Authority (MHRA) that it was safe to resume the British trials.
The patient involved in the study had been reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.
AstraZeneca, based in Cambridge, said it could not disclose further medical information.
"The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic," AstraZeneca said.
It declined to elaborate further on when other global trials were expected to restart.
The Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India.
Brazil's health regulator ANVISA said on Saturday evening it had approved the resumption of trials after reviewing data sent by the MHRA.
The Federal University of Sao Paulo, which is conducting the paused trials, said in a statement that 4,600 of the planned 5,000 volunteers have been recruited and vaccinated without any of them reporting any serious health issues.
Governments around the world are desperate for a vaccine to help end the pandemic, which has caused more than 900,000 deaths and global economic turmoil. The World Health Organization (WHO) had flagged AstraZeneca's as the most promising.
The vaccine is in late-stage clinical trials in the United States, Britain, Brazil and South Africa and additional trials are planned in Japan and Russia.
The UAE has been playing a stellar role in not just containing the spread of COVID-19 but in being a leader as far as vaccination initiatives go. The recently launched Wellness on Wheels (WoW) drive which is providing COVID-19 vaccination
A year into the pandemic, infection rates are falling. Hospitals are quieter; morgues are emptier. Emboldened by vaccines, we’re dropping our masks and stepping closer. Slowly we’re reopening indoor dining, theaters, museums and schools.
Across Britain, some people who have been counting down the days to their first COVID-19 jab are suddenly suffering doubts – among them my wife, Rachel, who was due to have it on Tuesday. The suspension of the roll out of the Oxford/AstraZeneca
This came during his meeting, on Tuesday, with Dr Susan Mumm, the new Chancellor of the American University Sharjah, in the presence of a number of members of the university's board of trustees and the vice-president in his office at the university.
Sheikh Mohammed tweeted, “All the best to the Kingdom of Saudi Arabia and its leadership. The Saudi National Day every year is a dear occasion to all of us; an occasion to express our fraternal relations and love and move to a better and more prosperous future for two peoples combined by a limitless ambition.”
The health ministry also announced that 62,694 doses of the COVID-19 vaccine were provided during the past 24 hours, bringing the total doses that have been provided to date to 19,549,263.